CLINICAL_TRIALS
trial_result
· 2022-03-29
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis [Phase 2]
Summary
Phase 2 study evaluating Imsidolimab (ANB019) in adults with Generalized Pustular Psoriasis has completed and posted results in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vanda Pharmaceuticals | Conditions: Generalized Pustular Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-03-29